Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-7237
Authors: Geyer, Martin
Keller, Karsten
Bachmann, Kevin
Born, Sonja
Tamm, Alexander R.
Ruf, Tobias Friedrich
Kreidel, Felix
Hahad, Omar
Petrescu, Aniela
Hell, Michaela
Beiras-Fernandez, Andres
Kornberger, Angela
Schulz, Eberhard
Münzel, Thomas
Bardeleben, Ralph Stephan von
Title: Concomitant tricuspid regurgitation severity and its secondary reduction determine long-term prognosis after transcatheter mitral valve edge-to-edge repair
Online publication date: 28-Jun-2022
Language: english
Abstract: BACKGROUND Concomitant tricuspid regurgitation (TR) is a common finding in mitral regurgitation (MR). Transcatheter repair (TMVR) is a favorable treatment option in patients at elevated surgical risk. To date, evidence on long-term prognosis and the prognostic impact of TR after TMVR is limited. METHODS Long-term survival data of patients undergoing isolated edge-to-edge repair from June 2010 to March 2018 (combinations with other forms of TMVR or tricuspid valve therapy excluded) were analyzed in a retrospective monocentric study. TR severity was categorized and the impact of TR on survival was analysed. RESULTS Overall, 606 patients [46.5% female, 56.4% functional MR (FMR)] were enrolled in this study. TR at baseline was categorized severe/medium/mild/no or trace in 23.2/34.3/36.3/6.3% of the cases. At 30-day follow-up, improvement of at least one TR-grade was documented in 34.9%. Severe TR at baseline was identified as predictor of 1-year survival [65.2% vs. 77.0%, p = 0.030; HR for death 1.68 (95% CI 1.12–2.54), p = 0.013] and in FMR-patients also regarding long-term prognosis [adjusted HR for long-term mortality 1.57 (95% CI 1.00–2.45), p = 0.049]. Missing post-interventional reduction of TR severity was predictive for poor prognosis, especially in the FMR-subgroup [1-year survival: 92.9% vs. 78.3%, p = 0.025; HR for death at 1-year follow-up 3.31 (95% CI 1.15–9.58), p = 0.027]. While BNP levels decreased in both subgroups, TR reduction was associated with improved symptomatic benefit (NYHA-class-reduction 78.6 vs. 65.9%, p = 0.021). CONCLUSION In this large study, both, severe TR at baseline as well as missing secondary reduction were predictive for impaired long-term prognosis, especially in patients with FMR etiology. TR reduction was associated with increased symptomatic benefit.
DDC: 610 Medizin
610 Medical sciences
Institution: Johannes Gutenberg-Universität Mainz
Department: FB 04 Medizin
Place: Mainz
ROR: https://ror.org/023b0x485
DOI: http://doi.org/10.25358/openscience-7237
Version: Published version
Publication type: Zeitschriftenaufsatz
License: CC BY
Information on rights of use: https://creativecommons.org/licenses/by/4.0/
Journal: Clinical research in cardiology
110
Pages or article number: 676
688
Publisher: Springer
Publisher place: Berlin
Issue date: 2021
ISSN: 1861-0692
Publisher DOI: 10.1007/s00392-020-01798-4
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
Thumbnail
concomitant_tricuspid_regurgi-20220627114547951.pdf1.04 MBAdobe PDFView/Open